DWTX
What one share of Dogwood Therapeutics holds
Pharmaceutical Preparations
We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Following the closing of the Combination described below, we became the sole owner of Pharmagesic (Holdings) Inc.
Dogwood Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.71 |
|---|---|
| Cash and investments | $0.29 |
| Book value | $2.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$52.50 | — | −$19.76 | — | $90.13 |
| 2021 | — | −$47.90 | — | −$47.09 | — | $43.52 |
| 2022 | — | −$27.66 | — | −$25.90 | — | $9.99 |
| 2023 | — | −$7.05 | — | −$6.48 | — | $4.94 |
| 2024 | — | −$12.52 | — | −$8.55 | — | −$7.60 |
| 2025 | — | −$7.13 | — | −$3.14 | — | $2.52 |